SCHEMBL15091096

SCHEMBL15091096

COC(=O)c1nnc(Cl)cc1Nc1ccc(C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.56
▸ AKR1C3 P42330 2/20 0.43
▸ AKR1C2 P52895 2/20 0.43
▸ MAPT P10636 6/20 0.43
▸ KDM4E B2RXH2 5/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ MITF O75030 1/20 0.43
▸ NPC1 O15118 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28359017 0.85 SYK (0.46) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL29922724 0.85 SYK (0.46) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL29922768 0.85 SYK (0.46) SYKKDM4ENPC1RAB9AALDH1A1
SCHEMBL28359050 0.85 SYK (0.46) SYKKDM4ENPC1RAB9AALDH1A1
SCHEMBL28359009 0.85 SYK (0.46) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL29922937 0.85 SYK (0.46) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL15091129 0.84 SYK (0.77) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL28362794 0.84 SYK (0.45) SYKAKR1C3AKR1C2MAPTKDM4E
SCHEMBL29922643 0.83 ALDH1A1 (0.47) SYKMAPTKDM4EKMT2ATDP1
SCHEMBL28359257 0.83 ALDH1A1 (0.47) SYKMAPTKDM4EKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2802567-B1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS HOFFMANN LA ROCHE (CH) 2017-03-01 — — EP disclosed
US-8901124-B2 Pyridazine amide compounds useful as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2014-12-02 — — US disclosed
EP-2802567-A1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-11-19 — — EP disclosed
WO-2013104573-A1 PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-07-18 — — WO disclosed
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS HOFFMAN-LA ROCHE INC. (US) 2013-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178478-A1 PYRIDAZINE AMIDE COMPOUNDS SYK, BTK, IRAK2 SYK 1/4885AKR1C3 3452/4885AKR1C2 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback